Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O 6 -Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
Federica MoranoAlessandra RaimondiFilippo PaganiSara LonardiLisa SalvatoreChiara CremoliniSabina MurgioniGiovanni RandonFederica PalermoLorenzo AntonuzzoNicoletta PellaPatrizia RaccaMichele PrisciandaroMonica NigerFrancesca CortiFrancesca BergamoAlberto ZaniboniMargherita RattiMichele PalazzoCeleste CagnazzoMaria Alessandra CalegariFederica MarmorinoIolanda CaponeElena ConcaAdele BusicoSilvia BrichElena TamboriniFederica PerroneMassimo Di MaioMassimo MilioneMaria Di BartolomeoFilippo de BraudFilippo PietrantonioPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The MAYA study provided proof-of-concept that a sequence of temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab may induce durable clinical benefit in MSS and MGMT-silenced mCRC.